Mixed adenocarcinoma, sarcomatoid carcinoma and adenosquamous carcinoma of the prostate: A case report

Adenosquamous carcinoma (ASC) and sarcomatoid carcinoma (SC) of the prostate are rare, but highly aggressive tumors. The occurrence of mixed carcinomas in the prostate is even more rarely reported. The present study reports the case of a 62-year-old male who was diagnosed with prostatic adenocarcino...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2014-11, Vol.8 (5), p.2325-2327
Main Authors: ZHANG, ZHONGFU, WANG, YADONG, ZHAO, QING, LI, GANHONG, ZHAO, XINGQI, LI, JUN, LI, XIANXIN
Format: Article
Language:English
Subjects:
Adenocarcinoma
adenosquamous carcinoma
Cancer therapies
Care and treatment
Case reports
Case studies
Complications and side effects
Development and progression
Hormone therapy
Metastasis
Mutation
Oncology
p53
Prostate cancer
prostate carcinoma
Proteins
Retention
sarcomatoid carcinoma
Studies
Urology
Vertebrae
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adenosquamous carcinoma (ASC) and sarcomatoid carcinoma (SC) of the prostate are rare, but highly aggressive tumors. The occurrence of mixed carcinomas in the prostate is even more rarely reported. The present study reports the case of a 62-year-old male who was diagnosed with prostatic adenocarcinoma accompanied by multiple bone metastases, as shown by a needle biopsy and skeletal computed tomography scan. The patient was treated with hormonal therapy, but thereafter, specimens from a transurethral resection of the prostate (TURP) were found to be composed of three histologically distinct elements: ASC, SC and adenocarcinoma. The level of p53 was evaluated by immunohistochemistry in detail, and it was found that this was significantly increased in the TURP samples compared with the needle biopsy samples. The abnormal level of p53 was likely associated with the prognosis of the patient; the patient succumbed to prostate carcinoma two months after the confirmation of the diagnosis.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2014.2493